CBS 2019
CBSMD教育中心
中 文

充血性心力衰竭

Abstract

Recommended Article

Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced The conductive function of biopolymer corrects myocardial scar conduction blockage and resynchronizes contraction to prevent heart failure Dapagliflozin for treating chronic heart failure with reduced ejection fraction Impact of epicardial adipose tissue on cardiovascular haemodynamics, metabolic profile, and prognosis in heart failure INTERMACS Profiles and Outcomes Among Non–Inotrope-Dependent Outpatients With Heart Failure and Reduced Ejection Fraction Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study Criteria for Iron Deficiency in Patients With Heart Failure Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction

Review Article2017 Nov;5(11):763-771.

JOURNAL:JACC Heart Fail. Article Link

Heart Failure With Mid-Range (Borderline) Ejection Fraction: Clinical Implications and Future Directions

Hsu JJ, Ziaeian B, Fonarow GC. Keywords: HFbEF; HFmrEF; HFpEF; epidemiology; heart failure with borderline ejection fraction; heart failure with mid-range ejection fraction; heart failure with preserved ejection fraction; outcomes

FULL TEXT PDF